Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 45Active not recruiting 9Unknown 3Terminated 3Withdrawn 2Suspended 2Recruiting 1

Sponsor Class

OTHER 9NETWORK 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2Lymphoid 1

Conditions

Neoplasms 14Multiple Myeloma 11Lymphoma 11Breast Neoplasms 10Melanoma 7Neoplasm Metastasis 6Colorectal Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Lung Neoplasms 5Leukemia 5Colonic Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroblastoma 3Neoplasms, Plasma Cell 3Mesothelioma, Malignant 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3

Interventions

pazopanib 1Dexamethasone 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NIH × Osteosarcoma × Clear all
NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

NCT01236586 2017-07-02

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinaryLymphoidSarcoma

Brain Neoplasms, Lymphoma, Neoplasms, Wilms Tumor, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡